产前糖皮质激素促胎肺成熟中的几个问题  

Discussion on prenatal corticosteroids for fetal lung maturation

作　　者：崔东 杨慧霞[1] Dong Cui;Huixia Yang(Department of Obstetrics and Gynecology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院妇产科,北京100034

出　　处：《中华围产医学杂志》2022年第6期470-471,共2页Chinese Journal of Perinatal Medicine

摘　　要：糖皮质激素促胎肺成熟在临床中已广泛应用,但孕期应用糖皮质激素可同时增加新生儿低血糖以及出生体重下降的风险。产前重复用药的优劣及具体方案等问题仍未达成共识。本文将结合英国皇家妇产科医师学会2022年2月公布的题为“降低新生儿病率和死亡率的产前糖皮质激素应用”指南,针对其中关于产前糖皮质激素使用的几点问题进行讨论。Prenatal corticosteroid for fetal lung maturation has been widely used in daily practice in obstetrics.However,previous research showed that prenatal corticosteroids may increase the risk of neonatal hypoglycemia and birth weight loss.And it remains controversial regarding the dosage and repeated administration.Based on the guideline"Antenatal corticosteroids to reduce neonatal morbidity and mortality"published by Royal College of Obstetricians and Gynaecologists in February 2022,here we are going to discuss several issues on the usage of prenatal corticosteroids.

关 键 词：糖皮质激素类 胎儿器官成熟度 肺 

分 类 号：R714.7[医药卫生—妇产科学]